Bisphosphonates Use After Total Joint Arthroplasty

National Defense Medical Center, Taiwan27,405 enrolled

Overview

Background Bisphosphonates has been associated with a decreased risk of revision total joint replacements because of its effects on decreased periprosthetic bone loss and prosthetic migration. However, the results in the early literature are inconsistent and the influence of bisphosphonates on associated complications and subsequent total joint arthroplasty (TJA) remains unknown. This study is to investigate the association between the use of bisphosphonates and risk of adverse outcomes after primary TJA. Materials and Methods This matched cohort study utilized National Health Insurance Research Database in Taiwan to identify patients who underwent primary TJA over a 15-year period (January 2000- December 2015 inclusive). Study participants were further categorized into two groups: bisphosphonates users and nonusers, using propensity score matching. The Kaplan-Meier curve analysis and adjusted hazard ratios (aHR) of revision surgery, adverse outcomes of primary surgery and undergoing subsequent TJA were calculated using Cox regression analysis.

Study Type

OBSERVATIONAL

Enrollment

27,405

Conditions

Diphosphonates

Interventions

Bisphosphonates, CombinationsDRUG

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients who underwent primary total joint arthroplasty during the study period (January 1, 2000 to December 31, 2015). Exclusion Criteria: 1. Patients with total joint arthroplasty before the index date, 2. Patients with existing pathologic fracture, nonunion of fracture and partial joint replacement, 3. Patients who were lost to follow-up 4. Patients \< 40 years old